Ignite Creation Date:
2024-05-05 @ 4:49 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00322036
Status:
TERMINATED
Last Update Posted:
2008-08-05
First Post:
2006-05-02
Brief Title:
Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimers
Sponsor:
Myrexis Inc
Organization:
Myrexis Inc
Study Overview
Official Title:
Phase 3 Multinational Randomized Double Blind Placebo Controlled Study of the Effect of Daily Treatment With MPC-7869 on Measures of Cognition Activities of Daily Living and Global Function in Subjects With Mild Dementia of the Alzheimers Type
Status:
TERMINATED
Status Verified Date:
2008-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Myriad has discontinued the development of Flurizan
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multinational randomized double blind placebo controlled parallel group study comparing the safety and efficacy of daily dosing of 800 mg twice daily MPC-7869 to placebo Study subjects will have the diagnosis of mild dementia of the Alzheimers type Subjects may be taking approved medication for Alzheimers disease provided the dose has been stable for at least 6 months
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None